Seeking Alpha

Amylin Pharmaceuticals (AMLN +13.5%) is among the early leaders after an injectable diabetes...

Amylin Pharmaceuticals (AMLN +13.5%) is among the early leaders after an injectable diabetes drug being developed along with partners Eli Lilly (LLY +0.7%) and Alkermes (ALKS +3.3%) receives a positive opinion from an EU panel. European regulators are expected to make a final decision within 2-3 months. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs